Nebenwirkungen · Briumvi
Briumvi 150 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9
HOS-150199 · Präparat HOS-100264
In active-controlled RMS trials, a decrease in neutrophils counts < LLN was observed in 15% of ublituximab patients compared with 22% of patients treated with teriflunomide. The majority of the neutrophil decreases were transient (only observed once for a given patient treated with ublituximab) and were Grade 1 (between <LLN and 1500 cells/mm3) and 2 (between 1000 and 1500 cells/mm3) in severity. Approximately 1% of the patients in the ublituximab group had Grade 4 neutropenia vs. 0% in the teriflunomide group. One ublituximab treated patient with Grade 4 (< 500 cells/mm3) neutropenia required specific treatment with granulocyte-colony stimulating factor.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-08T16:12:00Z · SHA-256 53c5ab94f9975d70ba11f2528f2ff97b611a29e4dee6edabccf82093c0699947 · Passage 755ef738d7777403f9a7d9f64618e281bb89a4023c8c4836ccfde9b12fc1aae5 · Zeichen 4126–4789 im Abschnitt